Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma

Launched by AIN SHAMS UNIVERSITY · Dec 20, 2022

Keywords

ClinConnect Summary

Malignant pleural mesothelioma is a rare but aggressive cancer of the pleural lining.

Malignant pleural mesothelioma accounted for 30,870 new cancer cases and 26,278 deaths worldwide in 2020.

In Egypt, Malignant pleural mesothelioma accounted for 337 new cases and 307 deaths in 2020.

Long-term exposure to asbestos is a well-established risk factor for Malignant pleural mesothelioma. It accounts for almost 80% of cases.

Malignant pleural mesothelioma is classified into three histologic subtypes: epithelioid, sarcomatoid, and biphasic. Epithelioid histology confers the most favorable prog...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Being at least 18 years old
• • Histologically or cytologically confirmed unresectable malignant pleural mesothelioma
• • ECOG Performance status 0-2
• • Completed at least four cycles of first line platinum (cisplatin or carboplatin) and pemetrexed combination chemotherapy before study entry
• • No evidence of disease progression following first-line treatment based on radiological criteria.
• • Adequate organ function is mandatory, defined as haemoglobin of at least 8.5 mg/dl, platelets of at least 100×10⁹ per L, and neutrophils of at least 1×10⁹/L.
• Exclusion Criteria:
• • Progression of disease after first line
• • Pregnant females
• • ECOG Performance 3-4
• • Patients with sarcomatoid mesothelioma
• • Patients who are candidates for curative surgery